APR 13, 2017 01:30 PM PDT

Ultra-sensitive single-molecule array (Simoa) technology to revolutionize CNS biomarkers

C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Chief Medical Officer (consulting), Quanterix Corp
      Andreas Jeromin, PhD, has more than 25 years of experience in CNS clinical diagnostics and companion diagnostics and co-authors more than 150 publications. He is the founder of Atlantic Biomarkers, Inc., and currently the consulting Chief Medical Officer to Quanterix Corp and member of several biomarker/CNS disorder consortia and working groups.


    The presentation will describe the principles of the ultra-sensitive single-molecule array (Simoa) developed by Quanterix and the application of the Simoa technology to the development of a toolbox of CNS biomarkers. The presentation will include several case studies across CNS diseases, ranging from traumatic brain injury to Alzheimer's Disease

    Show Resources
    Loading Comments...